Comparative Pharmacology
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE versus MYTESI.
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate is a synthetic opioid agonist that acts on mu-opioid receptors in the gastrointestinal tract to reduce peristalsis and prolong transit time. Atropine is added in subtherapeutic doses to discourage intentional overdose and provides anticholinergic effects.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
Each tablet contains diphenoxylate HCl 2.5 mg and atropine sulfate 0.025 mg. Adults: 2 tablets orally 4 times daily until diarrhea controlled, then reduce dose. Maximum 8 tablets per day for 2 days.
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Diphenoxylate: 2.5-12 hours (parent drug); difenoxin (active metabolite): 12-14 hours. Atropine: 2-4 hours. Clinical context: extended half-life of difenoxin allows twice-daily dosing for antidiarrheal effect.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Diphenoxylate is primarily excreted in feces via biliary elimination (approx. 50%) and renal excretion (approx. 50% as metabolites); atropine is mainly excreted renally (30-50% unchanged and metabolites).
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal